Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting

Jie Tang, PhD, Rui Kuai, MD, Wenmin Yuan, PhD, Lindsey Drake, MD, James J. Moon, PhD, Anna Schwendeman, PhD, *Corresponding authors at: Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.

Received 26 June 2016; accepted 10 April 2017

Abstract

Synthetic high-density lipoprotein nanoparticles (sHDL) are a valuable class of nanomedicines with established animal safety profile, clinical tolerability and therapeutic efficacy for cardiovascular applications. In this study we examined how the scavenger receptor B-I-mediated (SR-BI) tumor-targeting ability of sHDL, long plasma circulation half-life, and small particle size (9.6 ± 0.2 nm) impacted sHDL accumulation in SR-BI positive colorectal carcinoma cells, 3D tumor spheroids, and in vivo xenografts. We compared tumor accumulation of sHDL with that of liposomes (LIP, 130.7 ± 0.8 nm), pegylated liposomes (PEG-LIP, 101 ± 2 nm), and pegylated sHDL (12.1 ± 0.1 nm), all prepared with the same lipid components. sHDL penetrated deep (210 μm) into tumor spheroids and exhibited 12- and 3-fold higher in vivo solid tumor accumulation, compared with LIP (p < 0.01) and PEG-LIP (p < 0.05), respectively. These results suggest that sHDL with established human safety possess promising intrinsic tumor-targeted properties.

© 2017 Elsevier Inc. All rights reserved.

Key words: ApoA-I mimetic peptide; HDL; SR-bi; Tumor targeting; Surface modification

High-density lipoproteins (HDL), the smallest plasma lipoproteins known for their cardio-protective properties, have recently drawn attention as potential tumor targeting carriers and cancer therapeutics. Endogenous HDL nanoparticles are strongly resistant to recognition and elimination by the reticular endothelial system (RES) and display relatively long circulation times.1,2 In addition, compared with exogenous nanoparticles, HDLs are completely non-immunogenic, biodegradable, and biocompatible.3,4 Like other nanoparticles with the size range of several nanometers to hundreds of nanometers, HDL can extravasate through blood vessels and accumulate in the tumor tissue via the enhanced permeability and retention (EPR) effect.5 Furthermore, due to the ultra-small size (7–13 nm), HDL are expected to be able to use narrow interfibrillar openings (<40 nm) of interstitial collagens to penetrate deep into tumor tissues, which is crucially important for treatment of the solid tumors.6

Because a sustained and increased cholesterol supply is essential for tumor cell proliferation and progression, many tumor cells are known to overexpress HDL receptor-scavenger receptor B type I (SR-BI).7,9 This provides a specific target for HDL-mediated drug delivery and enables efficient tumor targeting without the need of complicated surface modifications. In addition, SR-BI mediated cholesterol efflux from tumor cells...
by cholesterol-free HDL may lead to cell cytotoxicity.\textsuperscript{10,11} Thus, HDL itself may serve as an anti-cancer agent especially when administered at high doses and in combination with chemotherapy.

Indeed, several groups have shown potential benefit HDL for treatment of cancer through cholesterol removal, cell metabolic starvation, and increased susceptibility to chemotherapy.\textsuperscript{10,11,13} While novel in the context of cancer therapy, reconstituted HDL (rHDL) have been used in other therapeutic realms for the past twenty years. Indeed, such nanoparticle preparations have been safely administered to over a thousand cardiovascular disease (CVD) patients at very high doses (8–135 mg/kg).\textsuperscript{14} Clinical benefits of these preparations have been reported, and are believed to stem from their ability to remove excess cholesterol from atherosclerotic plaques in the arteries and reduce a risk of heart attack.\textsuperscript{14–16}

Typically, to prepare rHDL, full-length apolipoprotein A-I (apoA-I) – the main protein component of endogenous HDL – is first purified from plasma and subsequently reconstituted with phospholipid. Clinical grade apoA-I has also been produced by a recombinant process, and several fully synthetic apoA-I mimetic peptides have been designed and clinically tested for treatment of cardiovascular diseases.\textsuperscript{17,18} Biomimetic HDL assembled from synthetic apoA-I peptides and phospholipids is referred to as synthetic HDL (sHDL).

Several important translational issues have been solved during the development of HDL for treatment of CVD, such as 1) how to prepare pure and homogenous rHDL and sHDL nanoparticles; 2) how the composition and administration route of sHDL and HDL affect their safety and efficacy; and 3) how to reduce the high cost of rHDL therapy by replacing full-length protein in rHDL with apoA-I mimetic peptides for preparation of sHDL. However, this recently acquired knowledge has not filtered to the world of HDL nanoparticle-based tumor targeting. Most published studies in sHDL tumor drug delivery focus on full-length apolipoproteins-based rHDLs that are technically challenging and costly to produce. In addition, apoA-I based rHDL are often heterogeneous in size and contain surfactants, host-cell proteins, endotoxin, and other impurities known to pose challenges for clinical safety and translation,\textsuperscript{19,20} whereas peptide-based sHDLs entirely made of chemically synthesized ingredients exhibit high degrees of homogeneity and purity.

In this study, we applied the apoA-I mimetic peptide ESP24218 (22A), which was previously developed for treatment of atherosclerosis.\textsuperscript{17} This peptide is not only a well-designed amphipathic helix with excellent lipid binding properties, but it has also been clinically tested as an sHDL nanoparticle - ETC-642. ETC-642 had been administered by intravenous amphipathic helix with excellent lipid binding properties, but it circulation half-life of approximately 12 h.\textsuperscript{17,18}

Clinical benefits of these trials, sHDL exhibited excellent safety and a long circulation half-life of approximately 12 h.\textsuperscript{17,18}

In this current study, we employed the protocol for sHDL synthesis that was established for clinical manufacturing of ETC-642,\textsuperscript{18} and performed systematic investigation of cellular uptake, tumor spheroids penetration, tumor accumulation, and in vivo distribution of sHDL carrying hydrophobic fluorescent dyes as a model drug and tracer. To gain further insights into sHDL-mediated drug delivery, we have synthesized sHDL and their pegylated counterpart (PEG-sHDL) and directly compared their tumor-targeting efficiencies with those of widely used tumor-targeting nanocarriers, namely liposomes (LIP) and pegylated liposomes (PEG-LIP), on a cellular, tissue-organ, and whole-body levels. Our results indicate that sHDL significantly enhance SR-BI mediated tumor targeting, tumor tissue penetration, and tumor accumulation, compared with LIP, PEG-LIP, and PEG-sHDL.

Methods

Materials

ApoA-I mimetic peptide 22A (PVLDLFRELLNEL-LEALKQKLK) was synthesized by Genscript Inc. (Piscataway, NJ). Peptide purities were determined by reverse phase HPLC to be >95%. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was generously donated by Nippon Oils and Fats (Osaka, Japan). Cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DSPE-PEG\textsubscript{2000}) were purchased from Avanti Polar Lipids, Inc. (Alabaster, Alabama). The fluorescent dyes 3, 3-dioctadecyloxacarbocyanine perchlorate (DIO), and 1,1'-dioctadecyl-3, 3, 3', 3'-tetramethylindotricarbocya-

nine iodide (DIR) were obtained from (Invitrogen, Carlsbad, CA). Polyclonal anti-SR-BI antibody was purchased from Novus Biological, Inc. (NB400–113, Novus Biologicals, Littleton, CO). All other materials were obtained from commercial sources.

Preparation and characterization of nanoparticles

The sHDL was prepared as described previously with slight modifications.\textsuperscript{21} Briefly, a mixture of 10 mg DPPC, 5 mg 22A in acetic acid, and 100 μg DIO in chloroform was freeze dried for 24 h. The lyophilized powder was reconstituted in 1 ml PBS (pH 7.4). The suspension was subsequently sonicated for 10 s in a bath sonicator and then homogenized to form sHDL. Pegylated sHDL (PEG-sHDL) was prepared with the same protocol as sHDL, but with the addition of DSPE-PEG\textsubscript{2000} at 5 mol % of DPPC in the beginning. Liposomes (LIP) were prepared by adding 10 mg DPPC, 0.5 mg cholesterol, and 100 μg DIO dissolved in chloroform. The mixture was dried under nitrogen flow for 2 h and then in a vacuum oven overnight at room temperature. The lipid film was rehydrated by 1 ml PBS (pH 7.4, 55°C). The suspension was sonicated for 2 min with a probe sonicator (50 W \times 10 S \times 12 cycles). The resulting multi-lamellar vesicles were sequentially extruded through polycarbonate membranes with pore sizes of 400, 200 and 100 nm by using a Mini-Extruder (Avanti Polar Lipids, Alabaster, AL) placed on a heating block pre-warmed to 55°C, to form small unilamellar vesicles. Similarly, to prepare pegylated liposomes (PEG-LIP), DSPE-PEG\textsubscript{2000} at 5 mol% of DPPC was added to the lipid mixture.

The average particle size and size distribution of sHDL, PEG-sHDL, LIP, and PEG-LIP were determined by dynamic light scattering (DLS) (Malvern, Westborough, MA). Samples were diluted to the final concentration of 1 mg/ml DPPC prior to testing. Sample purity was assessed by gel permeation chromatography (GPC) using Water’s Alliance HPLC equipped

Materials

ApoA-I mimetic peptide 22A (PVLDLFRELLNEL-LEALKQKLK) was synthesized by Genscript Inc. (Piscataway, NJ). Peptide purities were determined by reverse phase HPLC to be >95%. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was generously donated by Nippon Oils and Fats (Osaka, Japan). Cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DSPE-PEG\textsubscript{2000}) were purchased from Avanti Polar Lipids, Inc. (Alabaster, Alabama). The fluorescent dyes 3, 3-dioctadecyloxacarbocyanine perchlorate (DIO), and 1,1'-dioctadecyl-3, 3, 3', 3'-tetramethylindotricarbocya-

nine iodide (DIR) were obtained from (Invitrogen, Carlsbad, CA). Polyclonal anti-SR-BI antibody was purchased from Novus Biological, Inc. (NB400–113, Novus Biologicals, Littleton, CO). All other materials were obtained from commercial sources.

Preparation and characterization of nanoparticles

The sHDL was prepared as described previously with slight modifications.\textsuperscript{21} Briefly, a mixture of 10 mg DPPC, 5 mg 22A in acetic acid, and 100 μg DIO in chloroform was freeze dried for 24 h. The lyophilized powder was reconstituted in 1 ml PBS (pH 7.4). The suspension was subsequently sonicated for 10 s in a bath sonicator and then homogenized to form sHDL. Pegylated sHDL (PEG-sHDL) was prepared with the same protocol as sHDL, but with the addition of DSPE-PEG\textsubscript{2000} at 5 mol % of DPPC in the beginning. Liposomes (LIP) were prepared by adding 10 mg DPPC, 0.5 mg cholesterol, and 100 μg DIO dissolved in chloroform. The mixture was dried under nitrogen flow for 2 h and then in a vacuum oven overnight at room temperature. The lipid film was rehydrated by 1 ml PBS (pH 7.4, 55°C). The suspension was sonicated for 2 min with a probe sonicator (50 W \times 10 S \times 12 cycles). The resulting multi-lamellar vesicles were sequentially extruded through polycarbonate membranes with pore sizes of 400, 200 and 100 nm by using a Mini-Extruder (Avanti Polar Lipids, Alabaster, AL) placed on a heating block pre-warmed to 55°C, to form small unilamellar vesicles. Similarly, to prepare pegylated liposomes (PEG-LIP), DSPE-PEG\textsubscript{2000} at 5 mol% of DPPC was added to the lipid mixture.

The average particle size and size distribution of sHDL, PEG-sHDL, LIP, and PEG-LIP were determined by dynamic light scattering (DLS) (Malvern, Westborough, MA). Samples were diluted to the final concentration of 1 mg/ml DPPC prior to testing. Sample purity was assessed by gel permeation chromatography (GPC) using Water’s Alliance HPLC equipped
with a Tosoh TSKgel G3000SWxl (7.8mm × 30cm) column (Tosoh Bioscience, King of Prussia, PA). All the samples were diluted to the final concentration of 2 mg/ml DPPC and an injection volume of 25 μL was used. The samples were eluted with PBS (pH 7.4) at a flow rate of 1 ml/min and monitored by UV detection at 220 nm. Nanoparticles were diluted with PBS (pH 7.4), and further examined using transmission electron microscope (TEM) (Morgagni 268, FEI Company, Eindhoven, The Netherlands) at a voltage of 100 kV at 100,000-fold magnification.

**Cell culture**

HCT 116 cells were purchased from the ATCC (Manassas, VA) and cultured in McCoy's 5a Medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin. SR-BI-positive and -negative baby hamster kidney cells (BHK-SR-BI cells and BHK-mock cells) were gifts from Dr. Remaley (NHLBI, Bethesda, MD) and cultured in DMEM medium containing 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. To keep the transfected plasmid in BHK-SR-BI cells, 100 μg/ml Zeocin was added into the medium and SR-BI expression was induced by addition of 10 nM DIO.

**Confocal microscopy and flow cytometry**

Cells were seeded into 35 mm petri dishes with coverslip attached (10³/well) for confocal microscopy imaging, and into 6-well culture plate (2 × 10⁵/well) for flow cytometry studies. sHDL, PEG-sHDL, LIP, and PEG-LIP were added into wells at a DIO concentration of 5 μM, and incubated for 2 h at 37 °C. Cellular uptake was visualized using a Nikon A-1 Spectral Confocal microscope system (Nikon Corporation, Tokyo) with an excitation wavelength of 488 nm. Quantification of cellular fluorescent signal was determined using a cell sorter (Beckman Coulter FC500 5-color analyzer) at an excitation wavelength of 488 nm.

**Penetration of nanoparticle into tumor spheroids**

To investigate whether the uptake of HDL was mediated by the SR-BI, HCT 116 cells were pretreated with anti-SR-BI antibody (NB400-113, Novus biological) at a 1:100 dilution for 1 h at 37 °C. The cells were washed twice with PBS and incubated with 5 μM DIO loaded sHDL for 0.5 h at 37 °C, washed with PBS and analyzed by flow cytometry.

**In vivo fluorescence imaging**

DIR, which belongs to the same family fluorescent stains as DIO, is a widely used near infrared tracking dye for non-invasive whole body imaging due to its low tissue auto-fluorescence interference. DIR-loaded sHDL, PEG-sHDL, LIP, and PEG-LIP were prepared as described in the section of “Preparation and characterization of nanoparticles” with addition of 20 μg DIR instead of 100 μg DIO in the lipid mixture.

HCT 116 tumors were established in vivo by subcutaneous inoculation of 5 × 10⁶ cells in the left flank of the female athymic nude mice (Harlan Sprague Dawley, Inc. Indianapolis, IN). After 2 weeks, tumor-bearing mice were randomly divided into four groups with three mice each. DIR-loaded nanoparticles were intravenously injected at a dose of 200 μg/kg DIR. At the time points of 1, 12, 24, 48, and 72 h post injection, whole body optical imaging was taken using an IVIS Spectrum Imaging System (Caliper, Fullerton, CA).

**The stability of DIR loaded sHDL**

The remodeling of lipoproteins always happens in vivo, which may also cause the transfer of dye loaded in sHDL to other lipoproteins. To investigate whether the DIR signal remains in the HDL, DIR-loaded sHDL were incubated with serum at 37 °C under the shaking speed of 300 rpm. After 1, 6, or 24 h incubation, serum was passed through a Waters HPLC system equipped with Superose 6, 10/300 GL column (GE Healthcare, Piscataway, NJ), the fractions were collected every 30 s. All fractions were transferred into a 96-well black plate and the DIR fluorescence intensity was determined at the excitation and emission wavelengths of 748 and 780 nm, respectively. Thereafter, the concentration of total cholesterol in different fractions was determined using commercially available enzymatic kits (Wako Chemicals, Richmond, VA) and the elusion profiles of VLDL, IDL, LDL, and HDL were visualized based on the cholesterol signal.

**Statistics**

Statistical analysis was performed by Student’s t test. *P<0.05, **P<0.01, ***P<0.001, ns=no significant. Error bars are reported as standard deviations. All samples were performed in triplicate unless noted otherwise.
Results

Characterization of nanoparticles

Size distribution and purity of sHDL and liposomes were analyzed prior to their tests in vitro and in vivo. Dynamic light scattering (DLS) was used to characterize the average size and polydispersity (PDI) of nanoparticles. As shown in Figure 1, A, compared with the particle sizes of LIP (130.7 ± 0.8 nm) and PEG-LIP (100.9 ± 1.3 nm), sHDL and PEG-sHDL were much smaller, with average diameters of 9.6 ± 0.2 nm and 12.1 ± 0.1 nm, respectively. The size differences of nanoparticles were also observed in the gel permeation chromatography results (Figure 1, B), in which the retention times for sHDL and PEG-sHDL were ~8 min, while the retention times for both LIP and PEG-LIP were ~5 min, indicating much smaller sizes of sHDL nanoparticles. The small peaks at 11.6 min (<2% for all four groups) represent negligible levels of either free apoA-I mimetic peptide or free PEG-lipid moieties. Interestingly, we also found that the size of PEG-sHDL increased compared with non-pegylated sHDL, while the size of LIP became smaller after pegylation. This decrease in size of liposomes after pegylation may be due to the increase in the repulsive forces on the liposome surface after incorporation of the negatively charged DSPE-PEG and subsequent condensing of the inner hydrophilic cavity in liposomes.26,27 By contrast, sHDL is a nanodisc composed of a lipid bilayer wrapped around apoA-I mimetic peptide, like a belt, which thus lacks a hydrophilic inner cavity. Therefore, the presence of the PEG hydrophilic layer on the surface of sHDL nanodisc is thought to increase its hydrodynamic size. TEM micrographs showed that sHDL and PEG-sHDL had a typical nanodisc morphology with a uniform particle size (Figure 1, C). The nanoparticles sizes showed in TEM figures were consistent with the results from DLS and GPC. LIP and PEG-LIP nanoparticles had a typical unilamellar appearance and sizes similar to the DLS measured particle size values.

The comparison of nanoparticle uptake by SR-BI positive and negative cell lines

To investigate the contribution of scavenger receptor SR-BI on cellular uptake of nanoparticles, BHK cells with or without stable transfection of SR-BI were used. As shown in Figure 2, the DIO fluorescence signal observed in BHK-SR-BI cells after...
incubation with DIO-loaded sHDL was 3.6 times higher than that from BHK-mock cells, indicating that SR-BI played an important role in the cellular uptake of sHDL. The cellular uptake of DIO-loaded PEG-sHDL by BHK-SR-BI cells also increased, compared with BHK-mock cells, but its cellular uptake was much reduced compared with non-pegylated sHDL likely due to PEG interfering with receptor binding. In contrast, the expression of SR-BI on BHK cells had no apparent effect on the cellular uptake of LIP and PEG-LIP.

The cellular uptake of nanoparticles on HCT 116 cells

To better understand the effect of SR-BI on cellular uptake by cancer cells, HCT 116 cells - an SR-BI positive colon carcinoma cell line was used. As seen in the confocal microscopy images and flow cytometry in Figure 3, the fluorescence intensities of cells incubated with sHDL and LIP were much stronger than those incubated with PEG-sHDL and PEG-LIP. Importantly, we noted that DIO-loaded sHDL was diffusely and uniformly distributed within HCT 116 cells, which is characteristic of SR-BI-mediated cytosolic uptake of particles. In contrast, LIP was distributed in a punctate manner in HCT 116 cells, which is indicative of endocytosis-mediated particle uptake. To compare the effect of SR-BI on the cellular uptake of sHDL and LIP, we performed an inhibition study using an anti-SR-BI antibody. As shown in Figure 3, after incubation with the anti-SR-BI antibody, the cellular uptake of sHDL was decreased by 32%. This suggests that SR-BI plays an important role in the cellular uptake of sHDL although this pathway does not appear to be the sole mechanism of uptake. In contrast, the relatively high cellular uptake of LIP in HCT 116 cells was independent of SR-BI as there was no change in cellular uptake of LIP in the presence of anti-SR-BI antibody.

Factors influencing the cellular uptake of sHDL on HCT 116 cells

We also explored other factors that may affect the cellular uptake of sHDL by HCT 116 cells, including temperature, incubation time, and concentration. As shown in Figure 4, the cellular uptake of sHDL was inhibited with the decrease in the incubation temperature. In addition, the cellular uptake of sHDL increased significantly with both incubation time and sHDL concentration. Hence, cellular uptake of sHDL is a highly temperature-, time-, and concentration-dependent process.

Upon administration in vivo, cholesterol-free sHDL and PEG-sHDL are expected to take up cholesterol through cellular cholesterol efflux and interaction with endogenous lipoproteins, which would increase the particle size of sHDL and change in its membrane fluidity. To examine the potential influence of cholesterol loading on cellular uptake, we prepared sHDL and PEG-sHDL containing 5% molar ratio cholesterol and DIO and incubated them with HCT 116 cells. No statistically significant differences in HCT 116 cellular uptake were observed for cholesterol-loaded sHDL and
PEG-sHDL, compared to cholesterol-free nanoparticles (Supplementary Figure 1).

Penetration of nanoparticle into HCT 116 tumor spheroids

Evaluation of the ability of nanoparticles to penetrate tumors is critical because poor penetration into solid tumors is the major factor contributing to inadequate therapeutic effectiveness of nanoparticle-mediated delivery of cancer therapeutics. Three-dimensional (3-D) tumor spheroids on the scale of 200–500 μm have a morphology, function, and microenvironment similar to those of solid tumors; thus, they are a popular model for assessing drug penetration into tumor tissues. Here, we established HCT 116 tumor spheroids with an average size of 400 μm and imaged them by confocal microscopy to evaluate the penetration abilities of nanoparticles. As shown in Figure 5, after the 2-h incubation with LIP and PEG-LIP, the green fluorescence of DIO was very weak in the tumor spheroids, possibly due to the large sizes of liposomal carriers, compared with the small pores of interfibrillar openings (<40 nm) of interstitial...
collagens in tumor tissues. In contrast, the fluorescence signal was significantly stronger in the tumor spheroids after incubation with sHDL and PEG-sHDL (Figure 5, A). These results indicated that the size of nanoparticles played a crucial role in tumor penetration.

The average fluorescence intensity of DIO in each of the tumor spheroid cross-section was analyzed by Imaging Software NIS-Elements AR (Figure 5, B). The fluorescence signal decreased with the increase in the distance from tumor spheroid surface. At the center of the tumor spheroids, at approximately 210 μm distance from the surface, the fluorescence intensity of shDL was 2.4 times higher than that of PEG-shDL. The penetration difference between shDL and PEG-shDL groups was likely due to the efficient interaction between shDL with SR-BI followed by efficient cellular uptake of shDL, which could help keep the concentration gradient of nanoparticles in tumor spheroids.

In vivo fluorescence imaging

The non-invasive whole body imaging study was carried out to investigate the bio-distribution and tumor accumulation of nanoparticles in nude mice inoculated with human colon carcinoma HCT 116 cells. As shown in Figure 6, efficient tumor accumulation was observed in mice after administration of shDL and PEG-shDL, and the fluorescence intensities in the tumors were still obvious even up to 72 h after injection, indicating a long circulation time of these two nanoparticles in vivo. By contrast, LIP distribution was concentrated in the liver and spleen immediately after administration due to the capture and elimination by RES.

For imaging of individual organs after necropsy, fluorescence intensity for each organ was measured by the Living Image® software and reported as total photons per second per centimeter squared per steradian (p s⁻¹ cm⁻² sr⁻¹) (Figure 6, B and C). This is a widely reported method of studying biodistribution and organ accumulation of nanoparticles. Differences in organ accumulation were noted for liposomes and shDL groups with LIP and PEG-LIP accumulating in the spleen, whereas shDL and PEG-shDL showed higher accumulation in the lungs. In addition, efficient tumor accumulation for shDL and PEG-shDL was also achieved, and at much higher levels, compared with LIP and PEG-LIP groups. As

Figure 6. The in vivo imaging of HCT 116 tumor-bearing nude mice after administration of nanoparticles at 1 h, 12 h, 24 h, 48 h and 72 h. Tumors were located in the left flanks as indicated by the arrows (A). The ex vivo fluorescence images of isolated organs collected at 72 h post-injection (B). The average fluorescence intensities of tissues (C) and tumors (D) were analyzed using Living image® software. Data represent mean ± SD (n = 3). *, P < 0.05, **, P < 0.01 relative to shDL group.
shown in Figure 6, D, the fluorescence intensity of sHDL in isolated tumors was 12- and 3-fold higher than those of LIP (p < 0.01) and PEG-LIP (p < 0.05), respectively. Overall, these results suggest that sHDL with a relatively long circulation half-life can be efficiently targeted to tumors after a single administration.

Stability of DIR-loaded sHDL

To investigate stability of sHDL nanoparticles in serum, DIR-loaded sHDL were mixed with serum and incubated for up to 24 h. The serum lipoproteins were separated by size using gel permeation column chromatography (GPC). The signal intensity of DIR and the cholesterol distribution in each lipoprotein fraction was monitored (Figure 7). The reported size ranges of HDL, LDL, IDL, and VLDL are 5–15, 18–28, 25–50, and 30–80 nm, respectively.40 Here we first established a standard curve based on diameter-versus-retention time for the GPC column (data not shown) in order to correlate the sizes of different lipoproteins with various elution time (Figure 7, C). We found that most of DIR signal was from particles in the size range of HDL and we saw no evidence for DIR transfer to other lipoproteins. Immediately after mixing, the peak of DIR fluorescence shifted toward a slightly larger HDL size from 8.50 nm to 11.01 nm, which was likely due to cholesterol uptake by sHDL from endogenous lipoproteins. Overall, sHDL-DIR appeared to be stable in serum for up to 24 h.

Discussion

In this study we examined the ability of sHDL 1) to be taken up into the cytosol of colon carcinoma in an SR-BI receptor-mediated manner; 2) to penetrate tumor spheroids in vitro, and 3) to accumulate in solid tumors in vivo. As a prelude to this effort, we previously showed that sHDL itself has cytotoxic affect and, at least in adrenal carcinoma cells, works in synergy with chemotherapeutic agents.12 We have also reported that the anticancer drug, 10-hydroxycamptothecin (10HCPT), can be encapsulated in the bilayer of sHDL, leading to improved plasma half-life and cytotoxicity against colon carcinoma.41 In addition, we used sHDL to improve delivery of peptide antigens and adjuvants to the draining lymph nodes.42 In all cases, the phospholipid composition of sHDL had to be adjusted to improve stability of sHDL-drug complex. The 10HCPT was incorporated and retained in sHDL through physical partitioning in sphingomyelin bilayers, while peptide antigen was covalently conjugated through cysteine to a pyridyl-functionalized phospholipid. In all cases the homogeneity of size and discoidal shape of sHDL was retained upon drug incorporation. Thus, prior experience with preclinical safety, cGMP manufacturing and clinical administration of sHDL for cardiovascular applications could facilitate clinical translation of these nanoparticles as a potential cancer therapeutics or drug delivery carrier.

The size sHDL nanoparticles in this study was within the size range of native HDL (8–12 nm),43 which is smaller and more homogeneously sized than that reported for other cancer-targeted lipoprotein systems like HDL-mimicking peptide phospholipid scaffolds (HPPS) (15–25 nm spheres) or some of full-length apoA-I-based carriers (10–50 nm sizes).13,44-46 Particle purification post-assembly and incorporation of drugs/imaging agents is often required for other apoA-I or HPPS systems, which is often impossible to accomplish in a parenteral manufacturing suite under cGMP. Such purification is needed because of difficulties to control folding and reconstitution of full-length apoA-I, which leads to heterogeneity of sHDL particle size.47 By

Figure 7. The fluorescence intensity distribution (A) and the total cholesterol distribution (B) among different lipoproteins before and after the incubation of DIR-sHDL with serum. (C) The peaks in Figure A and B correspond to VLDL, IDL, LDL, and HDL respectively.
contrast, when apoA-I mimetic peptides are utilized for sHDL formation, their length, hydrophobic angle, and net charge often control nanoparticle purity and stability. The sHDL used in this study did not require purification post-assembly, as ESP24218 (22A) peptide was rationally selected from over 200 other sequences for its unique amphiphatic helix stability in vitro and in the presence of plasma components.

Similar to previously published reports on HPPS and apoA-I-based carriers, we found that DIO fluorescent dye cargo encapsulated in our sHDL was taken up directly into cytosol via the SR-BI receptor. Although some studies have previously proved that the cargos in sHDL were taken up by cells through a non-endocytic pathway, the efficient binding of sHDL with SR-BI receptor was still the first crucial step to facilitate the delivery of cargos into cells. In our study, modification of 5 mol % of sHDL lipids with PEG2000 reduced cellular uptake by 7.0-fold and 6.3-fold in SR-BI positive BHK and HCT-116 cells, respectively (Figures 2 and 3, B), likely due to steric hindrance effect of PEG on receptor binding. In addition, we found that only 32% of intracellular cargo delivery by sHDL is mediated by SR-BI in HCT-116 cells (Figure 3, C), indicating other cellular uptake pathways might be involved in sHDL internalization. Hence, gaining understanding of the relative contribution and variation of different cell uptake mechanisms within heterogeneous tumor cell types is important for future clinical translation.

Several recent papers have highlighted the importance of nanoparticle size for tumor penetration, in which smaller nanoparticles (≤ 20 nm) are found almost universally to diffuse more efficiently through tumor tissue than larger (~100 nm or greater) ones. We also found striking differences between sHDL, sHDL-PEG, LIP, and PEG-LIP in their ability to penetrate tumor spheroids (Figure 5). While minimal penetration was observed for LIP and PEG-LIP, the sHDL particle distributed through almost the entire tumor spheroid. In contrast, surface modification with 5 mol% PEG2000 reduced the fluorescence intensity at central sections of tumor spheroids by 58%, while the particle size increased only slightly from 9.6 nm to 12.1 nm. It is likely that sHDL owes its great tumor penetration ability to both small size and effective cell internalization by SR-BI receptor. Cellular uptake may reduce sHDL concentration in the intercellular matrix, thus creating a larger concentration gradient that drives further penetration of sHDL. Several studies have been performed to further improve sHDL tumor targeting and cellular uptake by surface modification with tumor-targeting ligands such as folate, EGF, and RGD.

While majority of HDL-cancer research is focused on drug delivery, recent studies indicate that even the drug-free sHDL exhibits intrinsic anti-cancer activity. This anti-cancer activity likely due to the ability of sHDL to efflux cholesterol from cancer cell via SR-BI receptor and, thus, avert cell metabolism. Normally the anti-tumor activity of drug-free sHDL is observed at relatively high dosages. For example, 100–200 μg/ml of 22A–sHDL was required to generate in vitro cytotoxicity in NCI-H295R and SW13 cells, and 250 mg/kg of R4F-sHDL was required to inhibit tumor growth in vivo. However, sHDLs are relatively safe and doses as high as 135 mg/kg of ApoA-I-based sHDL have been administered to patients, hence, sHDL-based cancer treatment could be feasible. In addition, the way sHDL induces cytotoxicity appears to be synergetic with traditional chemotherapeutic drugs, suggesting that lower doses of sHDL may be efficacious in vivo in combination with other therapeutics.

Appendix A. Supplementary data

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.nano.2017.04.009.

References


